| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/22/2015 | WO2015009787A1 Biomaterials comprising hyaluronic acid binding peptides and extracellular matrix binding peptides for hyaluronic acid retention and tissue engineering applications |
| 01/22/2015 | WO2015009744A1 Combinations comprising biphenyl derivatives for use in the treatment of hcv |
| 01/22/2015 | WO2015009742A2 Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain |
| 01/22/2015 | WO2015009731A2 Azacyclic constrained analogs of fty720 |
| 01/22/2015 | WO2015009616A1 Piperidinyl indole derivatives and their use as complement factor b inhibitors |
| 01/22/2015 | WO2015009615A1 Methods for the production of collagen iv |
| 01/22/2015 | WO2015009611A1 Inhibitors of leukotriene production |
| 01/22/2015 | WO2015009609A1 Inhibitors of leukotriene production |
| 01/22/2015 | WO2015009591A2 Treatment for melanoma |
| 01/22/2015 | WO2015009570A1 Ingestible canker sore treatment |
| 01/22/2015 | WO2015009545A1 Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators |
| 01/22/2015 | WO2015009533A1 Gabaa receptor antagonists affecting ganglion cell function and visual function |
| 01/22/2015 | WO2015009525A1 Azaindole compounds, synthesis thereof, and methods of using the same |
| 01/22/2015 | WO2015009500A1 Volatilized delivery of anatabine for treatment of substance addiction |
| 01/22/2015 | WO2015009407A1 Methods for promoting neuronal development and/or health comprising administration of a combination of docosahexaenoic acid and alpha-lipoic acid |
| 01/22/2015 | WO2015009406A1 Methods for promoting neuronal development and/or health |
| 01/22/2015 | WO2015009225A1 Food composition product |
| 01/22/2015 | WO2015009195A1 Optical isomers of (+) and (-)-benzhydryl ureas and (+) and (-)-1-[(3-chlorophenyl)-phenyl-methyl] urea, a pharmaceutical composition based thereon and a method for producing said optical isomers |
| 01/22/2015 | WO2015009149A1 Calcium-free dialysis fluid |
| 01/22/2015 | WO2015009008A1 Novel adenine derivative and use thereof |
| 01/22/2015 | WO2015008872A1 Cyanotriazole compounds |
| 01/22/2015 | WO2015008861A1 Novel imidazopyridine compound |
| 01/22/2015 | WO2015008849A1 Self-emulsifying composition of ω-3 fatty acid |
| 01/22/2015 | WO2015008848A1 SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
| 01/22/2015 | WO2015008844A1 Therapeutic agent for fgfr inhibitor-resistant cancer |
| 01/22/2015 | WO2015008839A1 Antitumor drug for intermittent administration of fgfr inhibitor |
| 01/22/2015 | WO2015008827A1 Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor |
| 01/22/2015 | WO2015008825A1 Orally disintegrating tablet |
| 01/22/2015 | WO2015008779A1 Novel pyranone carboxamide derivative and use thereof as anti-hepatitis c virus agent |
| 01/22/2015 | WO2015008317A1 Hydrogen sulfide production-inducing agent containing d-cysteine as active ingredient |
| 01/22/2015 | WO2015008301A1 Pharmaceutical composition for the treatment of diminution of bone tissue |
| 01/22/2015 | WO2015008246A1 New anti-malarial agents |
| 01/22/2015 | WO2015008234A1 Bicyclic heterocyclic compounds as ror gamma modulators |
| 01/22/2015 | WO2015008230A1 Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core |
| 01/22/2015 | WO2015008229A1 Autotaxin inhibitors |
| 01/22/2015 | WO2015008223A1 Treatment of hepatitis c virus infection with alisporivir and ribavirin |
| 01/22/2015 | WO2015008221A1 Novel crystalline forms of pemetrexed tromethamine salts |
| 01/22/2015 | WO2015008206A1 Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases |
| 01/22/2015 | WO2015008202A1 Indole-3-carbinol derivatives |
| 01/22/2015 | WO2015008195A1 Pamam dendrimer derivatives for antithrombotic therapy |
| 01/22/2015 | WO2015008138A1 Novel ureido derivatives of naphthalenesulfonic acids |
| 01/22/2015 | WO2015008073A1 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators |
| 01/22/2015 | WO2015008008A2 Use of compounds for restoring the response of the cells of the retina to light |
| 01/22/2015 | WO2015008007A1 Novel solanidine-derived compounds |
| 01/22/2015 | WO2015007896A1 Method for producing a 1-(5-halonaphthalene-1-sulfonyl)-1h-hexahydro-1,4-diazepine and composition comprising same |
| 01/22/2015 | WO2015007890A1 Pharmaceutical combinations of pregabalin |
| 01/22/2015 | WO2015007870A1 New compounds for the treatment and/or prevention of parasitic diseases and method of production of thereof |
| 01/22/2015 | WO2015007869A1 Local anesthetics and use thereof in cancer |
| 01/22/2015 | WO2015007830A1 Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| 01/22/2015 | WO2015007730A1 Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death |
| 01/22/2015 | WO2015007714A1 Sensitization of cancer cells to apoptosis induction by flavaglines and 5-hydroxy-flavones |
| 01/22/2015 | WO2015007676A1 Super quick disintegrating tablet formula for api miglitol |
| 01/22/2015 | WO2015007669A1 New azabenzimidazole derivatives |
| 01/22/2015 | WO2015007615A1 Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr) |
| 01/22/2015 | WO2015007613A1 O-alkyl triazolyl carbamates as inhibitors of fatty acid amide hydrolase (faah) |
| 01/22/2015 | WO2015007571A1 Powder mixtures for antibiotic dry syrup formulations |
| 01/22/2015 | WO2015007552A1 Ophthalmic compositions containing a nitric oxide donor |
| 01/22/2015 | WO2015007519A1 Novel benzimidazolium compounds |
| 01/22/2015 | WO2015007517A1 Novel tetra- and pentasubstituted benzimidazolium compounds |
| 01/22/2015 | WO2015007516A1 Novel 5-substituted benzimidazolium compounds |
| 01/22/2015 | WO2015007388A1 Salts of (e)-n-((1s,4s)-4-(dimethylamino)-1,4-diphenylcyclohexyl)-n-methylcinnamamide |
| 01/22/2015 | WO2015007326A1 Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases |
| 01/22/2015 | WO2015007249A1 N-alkyl tryptanthrin derivative, preparation method for same, and application thereof |
| 01/22/2015 | WO2015007222A1 EphA4 INHIBITORS AS NEUROPROTECTIVE AGENTS |
| 01/22/2015 | WO2015007219A1 Quinazoline derivatives, compositions thereof, and use as pharmaceuticals |
| 01/22/2015 | WO2015007206A1 Afatinib acid addition salts and crystal forms thereof, preparation method and pharmaceutical composition thereof |
| 01/22/2015 | WO2015007191A1 Paliperidone amino acids derivates and use thereof |
| 01/22/2015 | WO2015007181A1 5-BROMINE-2-(α-HYDROXYPENTYL)BENZOIC ACID SODIUM SALTS IN DIFFERENT CRYSTAL FORMS, AND PREPARATION METHOD THEREOF |
| 01/22/2015 | WO2015007129A1 Preparation of (-)-huperzine a |
| 01/22/2015 | WO2015007073A1 Quinine compounds, and optical isomers, preparation method and medical use thereof |
| 01/22/2015 | WO2015006893A1 Uses of sesquiterpene lactone compound and derivative thereof in preparation of drugs |
| 01/22/2015 | WO2015006875A1 Process for the preparation of substituted pyrimidines |
| 01/22/2015 | WO2015006863A1 Method of extracting flavonoids and/or polyphenols from dried and powdered orange peels, compositions therefrom, and methods of treatment of diseases associated with chronic inflammation |
| 01/22/2015 | WO2015006831A1 A method for reducing, inflammation, coagulation and adhesions |
| 01/22/2015 | WO2015006830A1 A method for organ arrest, protection and preservation and reducing tissue injury |
| 01/22/2015 | WO2015006829A1 A method for treating infection, sepsis and injury |
| 01/22/2015 | WO2015006828A1 A method for treating haemorrhage, shock and brain injury |
| 01/22/2015 | WO2015006827A1 A method for inducing whole body arrest |
| 01/22/2015 | US20150025511 Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| 01/22/2015 | US20150025480 Composition for the transdermal delivery of fentanyl |
| 01/22/2015 | US20150025443 Topical compositions to treat circulatory disorders |
| 01/22/2015 | US20150025439 Apparatus, system, and method for generating photo-biologic minimum biofilm inhibitory concentration of infrared light |
| 01/22/2015 | US20150025243 Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
| 01/22/2015 | US20150025240 Salts of prodrugs of piperazine and substituted piperidine antiviral agents |
| 01/22/2015 | US20150025233 Use of lipid conjugates in the treatment of diseases |
| 01/22/2015 | US20150025196 Polyoxazoline polymers and methods for their preparation, conjugates of these polymers and medical uses thereof |
| 01/22/2015 | US20150025155 Anti-prostate cancer compound and method of use thereof |
| 01/22/2015 | US20150025154 Ophthalmic composition |
| 01/22/2015 | US20150025153 Small Molecule CMKLR1 Antagonists in Demyelinating Disease |
| 01/22/2015 | US20150025152 Formulation and method of use of a treatment for shingles pain |
| 01/22/2015 | US20150025151 Compositions and methods for reducing body fat |
| 01/22/2015 | US20150025150 Methods and compositions for treating metabolic syndrome |
| 01/22/2015 | US20150025149 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
| 01/22/2015 | US20150025148 Alditol free, storage stable thyroid hormone active drug formulations and methods for their production |
| 01/22/2015 | US20150025147 Enhancer for eating activity and/or gastrointestinal activity |
| 01/22/2015 | US20150025146 Gastroretentive tablets |
| 01/22/2015 | US20150025143 Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance |
| 01/22/2015 | US20150025139 Ingenol mebutate in combination with cryotherapy for the treatment of actinic keratosis |
| 01/22/2015 | US20150025136 Treatment for Obesity |
| 01/22/2015 | US20150025134 Compositions and Methods for the Treatment of Sleep Apnea |